日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級(jí)生物類似抗體
  4. SLC34A2 (Lifastuzumab Biosimilar) Recombinant Monoclonal Antibody

SLC34A2 (Lifastuzumab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號(hào)：
    CSB-RA021581MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    SLC34A2（Lifastuzumab Biosimilar Antibody）重組單克隆抗體是一種靶向人源SLC34A2蛋白抗體，其別名為SLC34A2抗體、鈉依賴性磷酸轉(zhuǎn)運(yùn)蛋白2B抗體、NaPi3b抗體等，對(duì)應(yīng)溶質(zhì)載體家族34成員2（Solute carrier family 34 member 2）。該抗體以重組人SLC34A2蛋白制備，具有高度的種屬反應(yīng)性，主要針對(duì)人類樣本。 Lifastuzumab因其靶向的SLC34A2蛋白在多種惡性腫瘤中高表達(dá)，成為抗腫瘤治療的潛在藥物。研究表明，SLC34A2在非小細(xì)胞肺癌、乳腺癌、卵巢癌等實(shí)體瘤中異常激活，通過(guò)調(diào)控磷酸代謝參與腫瘤細(xì)胞的增殖與轉(zhuǎn)移。基于這一特性，Lifastuzumab作為靶向SLC34A2的單克隆抗體類似物，被開(kāi)發(fā)用于阻斷其生物學(xué)功能，目前已進(jìn)入臨床試驗(yàn)階段，探索其在晚期實(shí)體瘤患者中的療效與安全性，尤其在SLC34A2高表達(dá)腫瘤亞型中顯示出特異性治療潛力。 SLC34A2抗體廣泛應(yīng)用于腫瘤生物學(xué)機(jī)制研究。通過(guò)實(shí)驗(yàn)，可檢測(cè)細(xì)胞或組織中SLC34A2蛋白的表達(dá)水平與定位，助力揭示其在腫瘤發(fā)生發(fā)展中的作用機(jī)制。此外，該抗體可用于構(gòu)建腫瘤動(dòng)物模型，評(píng)估靶向SLC34A2類似物遞送系統(tǒng)或聯(lián)合治療方案的有效性，為開(kāi)發(fā)新型抗腫瘤藥物提供實(shí)驗(yàn)基礎(chǔ)。其高度的特異性和種屬反應(yīng)性，確保了在人類樣本研究中的可靠性與準(zhǔn)確性，成為腫瘤學(xué)研究領(lǐng)域的重要工具試劑。
  • Uniprot No.：
  • 基因名：
  • 別名：
    SLC34A2 antibody; Sodium-dependent phosphate transport protein 2B antibody; Sodium-phosphate transport protein 2B antibody; Na(+-dependent phosphate cotransporter 2B antibody; NaPi3b antibody; Sodium/phosphate cotransporter 2B antibody; Na(+/Pi cotransporter 2B antibody; NaPi-2b antibody; Solute carrier family 34 member 2 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human SLC34A2 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說(shuō)明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.
  • 基因功能參考文獻(xiàn)：
    1. The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2. PMID: 30262706
    2. SLC34A2 plays a crucial promoting role in colorectal cancer development. PMID: 29653487
    3. Studied expression of solute carrier family 34 member 2 (SLC34A2/NaPi2b) in epithelial ovarian cancer using monoclonal antibody MX35 and immunohistochemistry. Different staining intensities were observed in different grades of epithelial ovarian cancer. PMID: 28464843
    4. Low SLC34A2 expression is associated with non-small cell lung cancer. PMID: 26910912
    5. SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC. PMID: 28151475
    6. SLC34A2 was down-regulated in osteosarcoma patients.SLC34A2 interacted with PTEN, and decreased the phosphorylation of PI3K and AKT, which inactivated the PI3K/AKT signaling pathway. PMID: 28777670
    7. High expression of SLC34A2 was identified in about 2/3 patients and correlated with significantly better patient's overall survival. Epidermal growth factor receptor mutations were detected in about 53% of patients with no statistically significant difference to patient's overall survival. Anaplastic lymphoma kinase rearrangement was found in 8 out of 175 patients, harboring this abnormality leads to shorter overall survi PMID: 28720066
    8. we elucidated that miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC. Multivariate analysis identified miR-939, SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients. PMID: 28114937
    9. a novel role of SLC34A2 inbreast cancer stem cells (BCSCs) state regulation and establishes a rationale for targeting the SLC34A2/PI3K/AKT/SOX2 signaling pathway for breast cancer therapy. PMID: 28381172
    10. Knockdown of SLC34A2 inhibits proliferation. PMID: 28281971
    11. Our work sheds new light on the nature of the state of lung cancer stem cell-like cells and the role of SLC34A2 in the tumorigenicity of these cells PMID: 26846105
    12. our data indicated that SLC34A2 could exert significantly suppressive effects on tumorigenesis and progression of NSCLC. SLC34A2 might provide new insights for further understanding the early pathogenesis of human non-small cell lung cancer PMID: 26156586
    13. SLC34A2 might be associated with the initiation and progression of lung adenocarcinoma PMID: 25017204
    14. Data indicate that humanized monoclonal antibody Rebmab200 and murine monoclonal antibody MX35 monoclonal antibodies had similar specificity for sodium phosphate transporter NaPi2b. PMID: 23936189
    15. investigation revealed that the c.910A > T mutation in the SCL34A2 gene was responsible for pulmonary alveolar microlithiasis (PAM) patients in China PMID: 23164546
    16. identified 2 cases of pulmonary alveolar microlithiasis(PAM) with new mutations of SLC34A2 gene; identified the NaPi-IIb in a aortic valve; hypothesize that mutations in SLC34A2 may play a role in development of aortic valve calcification and arteriosclerosis PMID: 22336687
    17. a comprehensive analysis indicates that SCL34A2 is the only gene of the several phosphate transporters genes whose expression differentiates normal from carcinoma samples, suggesting it might exert a major role in ovarian carcinomas. PMID: 22553815
    18. The performed study revealed that SLC34A2 gene exhibited the most distinct change in expression and may become a molecular marker of papillary thyroid cancer PMID: 17091453
    19. study provides the data on the pattern of NaPi2b expression and cellular localization in breast, lung and ovarian cancers PMID: 21956469
    20. Upregulation of SLC34A2 gene expression in well-differentiated tumors may reflect cell differentiation processes during ovarian cancerogenesis and could serve as potential marker for ovarian cancer diagnosis and prognosis. PMID: 21716206
    21. There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71+/-0.77; tumour tissues: 10.29+/-0.80) among breast cancer tissues compared with normal tissues. PMID: 21036732
    22. In human lung alveolar epithelial cells, the content of calcium and phosphate in cell supernatant decreased with increased amount of SLC34A2 mRNA. PMID: 19134407
    23. study describes mutations in SLC34A 2 gene in an inbred Turkish family with three siblings diagnosed with pulmonary alveolar microlithiasis(PAM); findings suggest that impaired activity of the SLC34A2 gene may be responsible for familial PAM PMID: 20046000
    24. A novel mutation in exon 8 of the SLC34A2 gene were associated with pulmonary alveolar microlithiasis in Chinese pedigree. PMID: 20017296
    25. The current study was performed to characterize the minimal promoter region and transcriptional factor(s) necessary to activate gene expression of NaPi-IIb in human intestinal cells. PMID: 15458926
    26. Study identified a pulmonary alveolar microlithiasis locus by homozygosity mapping to 4p15, then identified, by a candidate-gene approach, the gene responsible for the disease as SLC34A2, which is involved in phosphate homeostasis in several organs. PMID: 16960801
    27. Mutations in the SLC34A2 gene that abolish normal gene function cause pulmonary alveolar microlithiasis. PMID: 17095743
    28. The monoclonal antibodies were shown to recognize specifically transiently overexpressed and endogenous NaPi2b in commonly used immunoassays. PMID: 18724815
    29. SLC34A2 is associated with sodium-lithium countertransport activity and blood pressure PMID: 19119262
    30. The gene responsible for PAM, SLC34A2, has been identified. It encodes a type IIb sodium-dependent phosphate transporter, the function of which provides an insight into the pathogenesis of this disease. PMID: 19617834

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Pulmonary alveolar microlithiasis (PALM)
  • 亞細(xì)胞定位：
    Membrane; Multi-pass membrane protein.
  • 蛋白家族：
    SLC34A transporter family
  • 組織特異性：
    Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 11020

    OMIM: 265100

    KEGG: hsa:10568

    STRING: 9606.ENSP00000371483

    UniGene: Hs.479372



×
生命科學(xué)計(jì)算平臺(tái)